Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-T cells (0413b0)
- Development stage
- Unknown
- Lead developer
- Henan Provincial Hospital of Traditional Chinese Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA CAR-T cells (specifically the HDS269B construct) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine. The therapy consists of a patient's own T cells engineered via gamma-retroviral transduction to express a second-generation CAR targeting the B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells in multiple myeloma. The CAR construct includes a 4-1BB costimulatory domain to promote T-cell expansion and persistence, along with a truncated epidermal growth factor receptor (tEGFR) that functions as a safety switch for cell depletion if needed. It is currently being evaluated in Phase I clinical trials for the treatment of relapsed or refractory multiple myeloma.
- Other names
- anti-BCMA CAR-TBCMA-targeted CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA CAR-T cells (0413b0).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-T cells (0413b0).